CRISPR Therapeutics stock could double by 2030 with promising gene editing treatments

From Nasdaq: 2025-05-18 09:30:00

CRISPR Therapeutics (NASDAQ: CRSP) has faced financial struggles despite clinical progress, with shares down 24% in the past three years. However, catalysts could double the stock price by 2030, with an estimated annual growth rate of 14.9%.

The company’s focus on gene editing has led to the development of Casgevy, a one-time treatment for sickle cell disease and beta-thalassemia. While Casgevy has not yet contributed significantly to financial results, it is expected to reach blockbuster status with an estimated market of 58,000 patients and $2.2 million per treatment course in the U.S.

CRISPR Therapeutics is working on promising candidates like CTX112 and CTX131 for cancer treatment, with potential data readouts expected this year. These developments could drive the company’s shares in the next five years.



Read more at Nasdaq: Prediction: This Beaten-Down Stock Could Double in The Next 5 Years